Allogene Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
ALLO$0.93-12.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share and per share data)
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance — December 31, 2020 (As Restated) | 140,474,305 | 140 | 1,725,552 | (712,503) | 268 | 1,013,457 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 1,961,554 | 2 | 8,344 | — | — | 8,346 |
| Vesting of early exercised common stock | — | — | 3,848 | — | — | 3,848 |
| Stock-based compensation | — | — | 80,818 | — | — | 80,818 |
| Employee stock purchase plan | 187,206 | — | 3,617 | — | — | 3,617 |
| Net loss (As Restated) | — | — | — | (182,051) | — | (182,051) |
| Net unrealized loss on available-for-sale investments | — | — | — | — | (2,835) | (2,835) |
| Balance — December 31, 2021 (As Restated) | 142,623,065 | 142 | 1,822,179 | (894,554) | (2,567) | 925,200 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 1,453,624 | 2 | 487 | — | — | 489 |
| Vesting of early exercised common stock | — | — | 2,905 | — | — | 2,905 |
| Stock-based compensation | — | — | 83,600 | — | — | 83,600 |
| Employee stock purchase plan | 361,615 | — | 2,461 | — | — | 2,461 |
| Net loss (As Restated) | — | — | — | (340,414) | — | (340,414) |
| Net unrealized loss on available-for-sale investments | — | — | — | — | (7,359) | (7,359) |
| Balance — December 31, 2022 (As Restated) | 144,438,304 | 144 | 1,911,632 | (1,234,968) | (9,926) | 666,882 |
| Issuance of common stock from ATM offering, net of commissions and offering costs of $1.7 million | 20,894,565 | 21 | 91,091 | — | — | 91,112 |
| Issuance of common stock upon exercise of stock options and vesting of RSUs | 2,718,410 | 3 | 2,084 | — | — | 2,087 |
| Vesting of early exercised common stock | — | — | 1,999 | — | — | 1,999 |
| Stock-based compensation | — | — | 65,951 | — | — | 65,951 |
| Employee stock purchase plan | 590,959 | 1 | 2,495 | — | — | 2,496 |
| Net loss | — | — | — | (327,265) | — | (327,265) |
| Net unrealized gain on available-for-sale investments | — | — | — | — | 8,971 | 8,971 |
| Balance — December 31, 2023 | 168,642,238 | $169 | $2,075,252 | $(1,562,233) | $(955) | $512,233 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.